ArticleCancer immunology, immunotherapy : CII2023

An alternatively spliced PD-L1 isoform PD-L1∆3, and PD-L2 expression in breast cancers: implications for eligibility scoring and immunotherapy response.

Didem Naz Dioken et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.